CRISPR

CRISPR1-cnr2

ID
ZDB-CRISPR-191031-13
Name
CRISPR1-cnr2
Previous Names
None
Target
Sequence
5' - ATGGCGTTTACGGGCTCTGT - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Constructs
No data available
Genomic Features
Genomic Feature Affected Genomic Regions
upr1 cnr2
Expression
Gene expression in Wild Types + CRISPR1-cnr2
No data available
Phenotype
Phenotype resulting from CRISPR1-cnr2
No data available
Phenotype of all Fish created by or utilizing CRISPR1-cnr2
Phenotype Fish Conditions Figures
response to absence of light increased occurrence, abnormal cnr2upr1/upr1 (NHGRI-1) chemical treatment: [6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-3-indolyl]-(4-methoxyphenyl)methanone Fig. 5 from Acevedo-Canabal et al., 2019
response to light stimulus decreased occurrence, abnormal cnr2upr1/upr1 (NHGRI-1) control Fig. 2Fig. 3Fig. 4Fig. 5 from Acevedo-Canabal et al., 2019
locomotory exploration behavior decreased occurrence, abnormal cnr2upr1/upr1 (NHGRI-1) control Fig. 2Fig. 3Fig. 5 from Acevedo-Canabal et al., 2019
locomotory exploration behavior decreased occurrence, abnormal cnr2upr1/upr1 (NHGRI-1) chemical treatment: HU-308 Fig. 5 from Acevedo-Canabal et al., 2019
locomotory exploration behavior decreased occurrence, abnormal cnr2upr1/upr1 (NHGRI-1) chemical treatment: JWH-133 Fig. 5 from Acevedo-Canabal et al., 2019
swimming behavior occurrence, abnormal cnr2upr1/upr1 (NHGRI-1) standard conditions Fig. 2 from Acevedo-Canabal et al., 2019
response to absence of light increased occurrence, abnormal cnr2upr1/upr1 (NHGRI-1) chemical treatment: JWH-133 Fig. 5 from Acevedo-Canabal et al., 2019
locomotory exploration behavior decreased occurrence, exacerbated cnr2upr1/upr1 (NHGRI-1) chemical treatment: pentetrazol Fig. 4 from Acevedo-Canabal et al., 2019
response to light stimulus decreased occurrence, abnormal cnr2upr1/upr1 (NHGRI-1) chemical treatment: HU-308 Fig. 5 from Acevedo-Canabal et al., 2019
response to light stimulus decreased occurrence, abnormal cnr2upr1/upr1 (NHGRI-1) chemical treatment: SR 144528 Fig. 5 from Acevedo-Canabal et al., 2019
response to light stimulus increased occurrence, exacerbated cnr2upr1/upr1 (NHGRI-1) chemical treatment: pentetrazol Fig. 4 from Acevedo-Canabal et al., 2019
response to absence of light increased occurrence, abnormal cnr2upr1/upr1 (NHGRI-1) chemical treatment: HU-308 Fig. 5 from Acevedo-Canabal et al., 2019
swimming behavior increased occurrence, exacerbated cnr2upr1/upr1 (NHGRI-1) chemical treatment: pentetrazol Fig. 4 from Acevedo-Canabal et al., 2019
response to light stimulus decreased occurrence, abnormal cnr2upr1/upr1 (NHGRI-1) chemical treatment: JWH-133 Fig. 5 from Acevedo-Canabal et al., 2019
response to absence of light increased occurrence, ameliorated cnr2upr1/upr1 (NHGRI-1) chemical treatment: valproic acid Fig. 3 from Acevedo-Canabal et al., 2019
locomotory exploration behavior decreased occurrence, exacerbated cnr2upr1/upr1 (NHGRI-1) chemical treatment: valproic acid Fig. 3 from Acevedo-Canabal et al., 2019
response to light stimulus decreased occurrence, abnormal cnr2upr1/upr1 (NHGRI-1) chemical treatment: valproic acid Fig. 3 from Acevedo-Canabal et al., 2019
response to absence of light increased occurrence, abnormal cnr2upr1/upr1 (NHGRI-1) control Fig. 2Fig. 3Fig. 5 from Acevedo-Canabal et al., 2019
Citations